Boston Scientific Exercises Option to Acquire Farapulse, Inc.
Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Read More

FARAPULSE’s Pivotal ADVENT Trial underway with First Patients Treated with its Breakthrough Pulsed Field Ablation System to Treat Atrial Fibrillation
Read More

FARAPULSE Receives European Approval To Commercialize Its Leading Pulsed Field Ablation System To Treat Paroxysmal Atrial Fibrillation
Read More

FARAPULSE Pivotal Trial to Assess Its Leading Pulsed Field Ablation System for The Treatment of Atrial Fibrillation Receives FDA Conditional Approval
Read More

Boston Scientific Announces Expanded Investment and Exclusive Acquisition Option Agreement with Farapulse, Inc.
Read More

FARAPULSE’s Pioneering Clinical Results at HRS Link Compelling Longterm Outcomes to Established Safety and Lesion Durability Data
Read More

FARAPULSE Extensively Showcased at Leading AF Symposium
Company’s technology and clinical progress detailed across more than 12 lectures/posters
Read More

FARAPULSE featured prominently at 2019 HRS Scientific Sessions
Late Breaking Clinical Trial Presentation and concurrent JACC publication highlight FARAPULSE technology’s potential to achieve new standard of care in treating Atrial Fibrillation
Read More

FARAPULSE Receives FDA Breakthrough Designation for its Endocardial Pulsed Field Ablation System
Late Breaking Clinical Trial Presentation and concurrent JACC publication highlight FARAPULSE technology’s potential to achieve new standard of care in treating Atrial Fibrillation
Read More